Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Atenativ in congenital antithrombin deficiency during surgery or delivery
2021-004307-40Phase 3Active
- Sponsor
- Octapharma
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of antithrombin III concentrate in congenital antithrombin deficiency (ATD), sponsored by Octapharma. Primary endpoint: Incidence of composite thrombotic and thromboembolic events. Started Nov 2021; status: active.
02
Drugs
antithrombin III concentrate
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on 2021-004307-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004307-40.